Latest
Breakthroughs, publications, and company milestones from Seek Labs.
Seek Labs has launched the Open Impact Sequence Ablation Therapeutics Program, a new Clinton Global Initiative Commitment to Action designed to advance therapeutic development for neglected and underserved infectious diseases using BioSeeker AI and Sequence Ablation Therapeutics.
Official announcements and press releases from Seek Labs.
Seek Labs has launched the Open Impact Sequence Ablation Therapeutics Program, a new Clinton Global Initiative Commitment to Action designed to advance therapeutic development for neglected and underserved infectious diseases using BioSeeker AI and Sequence Ablation Therapeutics.
Seek Labs and NAMRU EURAFCENT have entered a CRADA to evaluate field-deployable molecular diagnostics for infectious disease detection and biosurveillance.
Data support SeekIt™, the Company’s molecular diagnostic platform’s, potential to eliminate the long-standing tradeoff between molecular performance, speed and accessibility.
The science behind the platform. Peer-reviewed and editorial publications from the Seek Labs team.
Isothermal nucleic acid amplification offers advantages over qPCR for decentralized diagnostics but remains constrained by rigid primer design, detection complexity, and equipment dependence.
Seek Labs Publishes Editorial Review on the Future of CRISPR Antivirals in an Era of AI-Designed Viral Threats December 8, 2025 Read the full open-access review in Viruses Seek Labs today announced the publication of a new editorial review in Viruses (MDPI), authored by Alison O’Mahony, Senior VP of Research, and Douglas P. Gladue, VP…
Seek Labs Publishes First Peer-Reviewed Paper Demonstrating A CRISPR-Based Therapeutic Is Effective Against African Swine Fever November 17, 2025 SALT LAKE CITY, UT (Business Wire) – Seek Labs, a biotechnology company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the publication of a peer-reviewed paper in Viruses (MDPI),…
Perspectives on programmable medicine, platform innovation, and the future of disease response.
AI-designed viruses are becoming a reality. Learn how programmable CRISPR could help build faster defenses against emerging and engineered viral threats.
Discover how Seek Labs developed ANINA™, a novel isothermal amplification chemistry for molecular accuracy without laboratory infrastructure.
Seek Labs recently announced BioSeeker has mapped CRISPR-addressable regions across all 25 viral families known to infect humans. That is an important infectious disease milestone.
Ebola Isn’t One Virus. We’ve Been Treating It Like One. By Jared Bauer, CEO Ebola Bundibugyo (BDBV) is the strain driving the current outbreak in the Democratic Republic of the Congo and Uganda — and it is one the world is dangerously unprepared for. “No vaccine exists. No therapy exists. The virus circulated undetected for…
For Continuously Evolving Threats like Avian Influenza, We Must Design Durable Anti-Viral Therapeutics Highly pathogenic avian influenza (HPAI) illustrates a clear and urgent application for Seek Labs’ platform based programmable therapeutic. By Dr. Douglas Gladue | March 11, 2026 Highly pathogenic avian influenza (HPAI) is a persistent and economically disruptive disease threat. It has been…
Next Generation CRISPR: How Seek Labs’ Programmable Therapeutics Are Expanding the Promise of CRISPR-Powered Innovation At Seek Labs, every day is World CRISPR Day. Our work in programmable therapeutics builds upon the same principles that make CRISPR so revolutionary: precision, adaptability, and speed. As we reflect on this transformative technology, we’re not just looking at…
Seek Labs has launched the Open Impact Sequence Ablation Therapeutics Program, a new Clinton Global Initiative Commitment to Action designed to advance therapeutic development for neglected and underserved infectious diseases using BioSeeker AI and Sequence Ablation Therapeutics.
It’s a scenario that happens across the world, and it’s a major driver of antibiotic resistance. A patient wanders into a clinic with a sore throat or coughing and congested. The doctor knows the sore throat or respiratory infection is likely caused by a virus, which antibiotics can’t kill, but today’s diagnostic tools don’t allow…
Seek Labs received first place in the BioTech and Therapeutics category of the 2026 Utah Business Innovation Awards for its novel Sequence Ablation Therapeutics (SAT) modality.
In May, Naval Medical Research Unit (NAMRU) EURAFCENT entered into two cooperative research and development agreements (CRADAs) with Seek Labs.
Seek Labs and NAMRU EURAFCENT have entered a CRADA to evaluate field-deployable molecular diagnostics for infectious disease detection and biosurveillance.
AI-designed viruses are becoming a reality. Learn how programmable CRISPR could help build faster defenses against emerging and engineered viral threats.
Discover how Seek Labs developed ANINA™, a novel isothermal amplification chemistry for molecular accuracy without laboratory infrastructure.
Data support SeekIt™, the Company’s molecular diagnostic platform’s, potential to eliminate the long-standing tradeoff between molecular performance, speed and accessibility.
BIO 2026: Where Pharma leaders Say AI Hasn’t Delivered This article was written by Meagan Parrish and originally published on PharmaVoice.com on June 26, 2026. Read the original story here. AI hasn’t always been what it was cracked up to be in pharma. Here’s where execs say the technology hasn’t lived up to the hype.…
Stay connected
Stay connected to company milestones, scientific insights, and the work unfolding across BioSeeker, SAT, and Seek Diagnostics.